Partners
Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and significantly improve lives.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
Eagle Labs is building a platform to connect the UK’s entrepreneurial ecosystem to drive digital skills development to help grow the economy through innovation and change.
Barclays is on a mission to help make the UK the best place to start and grow innovative businesses by promoting creativity and entrepreneurship. Through our activities, we create opportunities for individuals and businesses of all sizes to access a broad range of skills to support this mission.
Eagle Labs also support the transformation of businesses, industries and larger organisations through the delivery of structured innovation programming and access to new and emerging technologies.
With Eagle Labs all over the UK and more in the pipeline, our aim is to provide high-potential businesses with the services they need to help their businesses. From each location we cultivate a community of likeminded entrepreneurs who benefit from access to a collaborative co-working and office space, structured mentoring and a curated events programme.
We are an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all.
Operating in 149 countries, we have 22,000 collaborators employed worldwide and a turnover of 4.176 billion euros in 2018. Entirely independent, we are able to reinvest 25% of our total revenue (excluding generics) into Research and Development, and all profits are used for further development.
Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular and immune-inflammatory diseases, neuropsychiatric disorders, cancer and diabetes. We are a leading force in cardiology—number 2 in Europe, number 8 worldwide—and oncology has become a top priority in recent years; we also manufacture high-quality generic drugs.
Our three research centres are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in our 16 production centres around the world. We have an active partnership policy in the field of biotechnology and we are investing in e-health through our internal WeHealth by Servier initiative.
All our employees are driven by shared values and guided by a common vision. Together we share the passion of entrepreneurship and we are committed to therapeutic progress to serve patient needs.
Johnson & Johnson Innovation seeks to positively impact human health through innovation.
Johnson & Johnson Innovation in EMEA focuses on accelerating all stages of innovation across the region and forming collaborations between entrepreneurs and the Johnson & Johnson Family of Companies. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer sectors.
In our Pharmaceuticals sector we are divided into six therapeutic areas that run disease and pathway focused portfolios, which are fuelled by world class functions. In our areas of focus*, we drive research from inception/idea through new indications for marketed products until loss of exclusivity.
Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators – through our Innovation Centre in London, UK, our incubator JLABS @ BE in Belgium, our strategic venture capital arm Johnson & Johnson Innovation – JJDC, Inc. and our Janssen Business Development teams – to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in consumers and patients. For more information about Johnson & Johnson Innovation, please visit: www.jnjinnovation.com or follow us on Twitter @jnjinnovation.com
* Cardiovascular & Metabolism (metabolism, retinal diseases, thrombosis), Immunology (IBD, rheumatology, IL-23 pathway), Infectious Diseases and Vaccines (hepatitis, respiratory infections, bacterial vaccines, viral vaccines), Neuroscience (mood disorders, neurogenerative disorders, schizophrenia, glutamatergic pathway diseases), Oncology (hematologic malignancies, solid tumor targeted therapy, prostate cancer, immuno-oncology), Pulmonary Hypertension (Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension)
The Astellas Group’s business philosophy has three elements — raison d’être, mission and beliefs.
Raison D’être
Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products
– To go beyond all others in exploring and tapping the potential of the life sciences.
– To continue tackling new challenges and creating innovative pharmaceutical products.
– To deliver quality products along with accurate information and retain solid credibility among customers.
– To support healthy living for people around the world.
– To continue shining on the global pharmaceutical field.
Mission: Sustainable enhancement of enterprise value
Astellas will seek to enhance its enterprise value in a sustainable manner. Astellas will seek to be the company of choice among all its stakeholders, including its customers, shareholders, employees, and the global community. Astellas will strive to gain the trust of all stakeholders and thereby enhance its enterprise value.
Beliefs: Our “beliefs” provide the code of conduct we prize at all times. Astellas will always be a group of people who act upon these beliefs.
High Sense of Ethics: We will always manage our business with the highest sense of ethics.
Customer Focus: We will always seek to understand customer needs and our focus will always be on achieving customer satisfaction.
Creativity: We will not be complacent and will always seek to innovate to create new value.
Competitive Focus: Our eyes will always be directed to the outside world, and we will continue to create better value faster.
Astellas promises to perform its obligations toward all stakeholders by acting ethically and seeking to actively disclose information.
At KISS, we keep it successfully simple. Our proven ability to cut through complexity and deliver standout results has enabled us to build our reputation and win a fantastic family of clients in science, technology, education and affiliated sectors. Our expert team of specialists in strategy, branding, digital and public relations work side-by-side to create and deliver distinctive ideas that will surprise you, worry the competition and add value to your business.
The Quadram Institute will create new interfaces between food science, gut biology, human health and disease, capitalising on the world-class bioscience cluster based at the Norwich Research Park. Scientists working with clinicians will work closely with major national and international funding bodies and charities, collaborators and investors to ensure translation of our fundamental science to benefit patients, consumers and wider society.
The mission of the Quadram Institute is to understand how food and the gut microbiota are linked to the promotion of health and the prevention of disease, with an emphasis on diet- and age-associated diseases. We will use this knowledge to develop evidence-based strategies to maximise positive impacts of food on health, from early life to the extension of a healthy lifespan in old age, and reduce the economic and societal costs of chronic diseases.
The Quadram Institute – an interdisciplinary institute to maximise the unique cluster of academic excellence and clinical expertise at the Norwich Research Park, working alongside the food and pharmaceutical industries
Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system (CNS).
We are pioneers of fragment-based drug discovery (FBDD); the most important advance in discovery chemistry in the last 20 years. Our FBDD platform, “Pyramid™”, has been successfully applied to therapeutic targets addressing a variety of disease areas. We also have a number of partnered products arising from drug discovery collaborations with major pharmaceutical companies.
Lifebit is democratising muti-omics, biomedicine & big data analysis with its AI-powered cloud-based system. This enables developers & researchers, no matter their computational & data analysis training level, & their corresponding organisations (ie. startups, SMEs, pharmaceutical companies), to instantly run & scale such analysis in a cost-speed-efficient and reproducible way that automates the analysis processes, learns from the data and provides actionable insights.
Our Vision is to be recognized by our customers as leading provider of Artificial Intelligence based products offering best in class data crawling, aggregation, analysis and visualization solutions. We enable customers to succeed in a competitive market by delivering real time access to full picture of relevant data. We continuously develop our products based on Artificial Intelligence to enable broader, deeper and faster insights and best found decision making.
The Microbiotica platform is based on world leading tools developed at the Wellcome Trust Sanger Institute that unblock the barriers to discovery. These are founded on a unique capability to culture, characterise and phenotype the majority of a patient’s gut bacteria, enabling precise association of bacteria to function for the first time. They also include the leading microbiota culture collection and reference genome database which provide resources for precise metagenomic analysis and functional studies, and humanised in vitro and in vivo models of disease. Using these tools Microbiotica starts programs with deep analysis of samples from clinical trials and progresses medicines and biomarkers through lab testing back into the clinic.
Oxford Nanopore Technologies has developed the world’s first nanopore DNA and RNA sequencing devices. The MinION is a portable, real-time, long-read, low-cost device designed to bring easy biological analyses to anyone, whether in scientific research, education or real-world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or microgravity biology.
Nanopore sequencing is used by a thriving community of thousands in more than 70 countries, enabling a myriad of applications within the laboratory environment and in the field. The GridION and PromethION devices serve users with larger projects or more samples. Oxford Nanopore Technologies products are currently for Research Use Only. Not for use in diagnostic procedures
Cambridge Innovation Capital (CIC) is a £275 million venture capital fund building IP rich life science and technology businesses in the Cambridge ecosystem.
CIC combines a unique relationship with the University of Cambridge with deep financial and industry links to build leading businesses out of the rapidly growing, intellectual property rich companies from the University of Cambridge and the Cambridge ecosystem.
Biotechgate is the global lead sourcing database for the Biotech, Pharma and Medtech industries. Identify potential business partners, new leads and benchmark your deals.
- Over 20,000 Biotech, Pharma and Medtech assets available for licensing
- Over 50,000 companies including management contacts, products and financing rounds
- Unique dataset and data management process
- Small Biotech, Medtech and Pharma companies
- Collaboration with a worldwide network of over 30 cluster organizations
- Benchmark license agreements with financial information
MediWales is the life science network for Wales. We are a not for profit, independent membership organisation, providing advice, support and business opportunities for our members. We have over 180 members including life science organisations, pharmaceutical services, medical technology companies, academia and the Welsh NHS. At Connects 2019, NHS colleagues from across Wales, local companies and the wider industry sector will join to share clinical innovation in practice to improve patient outcomes. The event includes keynote presentations, CPD training seminars, workshops and an exhibition.
Be present in Greater Copenhagen Life Science
Greater Copenhagen Life Science is the primary mouthpiece for the Medicon Valley region’s many companies and organizations within biotech, medtech and pharma as well as companies who have this segment as their customers or suppliers.
The magazine is a place of gathering for all companies in Danish and Nordic life science and presents a unique opportunity to survey the whole scene of the people and businesses that make up the life science industry. Greater Copenhagen Life Science is a high-quality magazine that weights validity and thoroughness highly. Therefore we have joined forces with a strong team consisting of life science journalists.
The publications offer companies a unique opportunity to brand themselves both nationally and internationally. The printed magazines are mainly distributed in Denmark, Sweden and Norway to:
• Named decision-makers in the life science industry
• Investors
• Science parks
• Hospitals
• Universities
• Laboratories
• Life science media
• Relevant MPs in Scandinavia
• National and international trade fairs, conferences and exhibitions in Europe, North America and Asia.
Greater Copenhagen Life Science is also published online to our readers all around the world, mainly in Europe, the US, India etc. The online publication is distributed directly by e-mail and is to be found online at any time on our home page and partner sites.
Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.
News Medical is an online, open-access hub for medical and life sciences professionals, and engaged consumers. With visitors from over 200 countries, News Medical is regarded as a world leader in the distribution of online medical and life science information. Our dedicated team of experts produce news stories, encyclopaedic articles, webinars and white papers every day. We also conduct exclusive interviews with Thought Leaders and Industry Professionals, providing our readers with a unique insight into the people behind the research.
Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative life sciences in the UK. Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.
Our members include:
- Start-ups, biotechnology and innovative life science companies
- Pharmaceutical and technological companies
- Universities, research centres, tech transfer offices, incubators and accelerators
- A wide range of life science service providers: investors, lawyers, IP consultants, IR agencies
We promote an ecosystem that enables innovative life science companies to start and grow successfully and sustainably, and we do this through Influence, Connect, Save.
BioPartner UK is the independent, accredited trade organisation that promotes international partnering for trade, investment and collaborations with UK life science enterprises. BioPartner’s UK Delegations promote the UK presence at international conferences. We work with conference organisers, in-country agencies and overseas networks to provide the best business opportunities for our members and UK companies travelling with outward delegations. BioPartner also provides access to government grants and entry fee discounts for all UK-based organisations.
BioPartner Mission Statement
To assist UK Life Science companies in their aims to internationalise, providing practical support through partnerships with Government and industry expertise.
The Cambridge Independent has won three UK Regional Newspaper of the Year awards since it was launched in 2016 by family-owned, independent publisher Iliffe Media.
Based at Iliffe Print Cambridge, where we print all 30-plus titles now in our group, it offers a thought-provoking look at news, sport, business, culture and more for the Cambridge region, and pays special attention to the worlds of science and technology.
A dedicated Science spread every week features interviews with leading lights in the Cambridge research community, while our Business pages celebrate the achievements of the region’s outstanding business community.
Editor Paul Brackley said: “We are proud to support Cambridge Biotech Week and the Health Horizons Future Healthcare Forum.”
Europe’s leading seed accelerator.
We are thinkers and doers with a mission to improve the quality of lives and our environment through innovation. We team up with top startups to nurture and fuel growth.
We do it because we truly believe that they are the heroes who will create solutions for some of the biggest challenges of our time. Whether you’re a startup looking for hands-on support or a corporation seeking innovation you’ll find that we’re a bunch of passionate people with a strong sense of execution and above all, a willingness to get our hands dirty.
Medicon Valley Alliance (MVA) is a non-profit membership organization in the Danish-Swedish life science cluster Medicon Valley, which is a part of Greater Copenhagen. Their +250 members represent the region’s triple helix and include universities, hospitals, human life science business, regional governments and service providers. They create value for their members by co-hosting, launching and driving meetings, networks, seminars, conferences and projects, that strengthen the collaboration, networking and knowledge-sharing in the regions life science community, create critical mass and help realizing the full potential of Medicon Valley.
The MVA vision is to be a well-known and respected member driven contributor to the realization and positioning of Medicon Valley as the most competitive and vital life science cluster in northern Europe. They are always searching for innovative ways to make Medicon Valley an even more integrated and attractive bi-national life science cluster. Synergy is the key to this.
EBD Group is the leading partnering firm for the global life science industry. Their mission is to facilitate the critical, strategic connections that drive life science dealmaking. EBD specializes in bringing people together, whether face-to-face at one of their leading global life science partnering events powered by partneringONE, or virtually through their online community of dealmakers and thought-leaders.
Thee Babraham Research Campus is considered to be one of the UK’s leading campus’ to support early-stage bioscience enterprise and is distinct in its co-location of bioscience companies with the Babraham Institute. World class research and business come together to promote innovation and strengthen links between academia and the commercial world. The Babraham Research Campus is managed and developed by Babraham Bioscience Technologies Ltd (BBT).